RJA
KNSA icon

Raymond James & Associates’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Raymond James & Associates’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-54,794
Closed -$624K – 4219
2021
Q3 		$624K Sell
54,794
-4,424
-7% -$57.6K ﹤0.01% 2901
2021
Q2 		$825K Buy
59,218
+21,458
+57% +$326K ﹤0.01% 2723
2021
Q1 		$699K Sell
37,760
-13,645
-27% -$279K ﹤0.01% 2764
2020
Q4 		$908K Buy
+51,405
New +$903K ﹤0.01% 2414

Other funds holding KNSA

PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Raymond James & Associates's KNSA Position: Q4 2021 in Review

Raymond James & Associates sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2021, closing a stake of 54,794 shares — an estimated $624K sold.

Raymond James & Associates first reported a position in KNSA in Q4 2020 and held it in 4 quarters. The position peaked at $908K in Q4 2020. 103 funds tracked by Wall St. Rank hold KNSA as of Q4 2021.

  • Raymond James & Associates reported no remaining Kiniksa Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 54,794 Kiniksa Pharmaceuticals shares in Q4 2021, an estimated $624K.
  • Raymond James & Associates first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Raymond James & Associates's Kiniksa Pharmaceuticals position peaked at $908K in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.